Core Insights - Dianthus Therapeutics has appointed Simon Read, Ph.D., to its Board of Directors, bringing over 30 years of biopharmaceutical leadership and expertise [1][2] - The company is focused on advancing its mid- and late-stage clinical programs, particularly the DNTH103 therapy for severe autoimmune diseases [2][3] - Lonnie Moulder will transition from the Board, having played a significant role in the company's growth from a private entity to a publicly traded company with three ongoing clinical trials [2] Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation antibody complement therapeutics aimed at treating severe autoimmune and inflammatory diseases [3] - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharma executives [3] Leadership Background - Dr. Read previously served as CEO and founder of Mariana Oncology until its acquisition by Novartis in 2024 and as Chief Scientific Officer at Ra Pharma until its acquisition by UCB in 2020 [1][2] - He has held leadership roles in R&D at major pharmaceutical companies, including GlaxoSmithKline, AstraZeneca, and Roche/Genentech, contributing to the development of well-known immunology drugs [2] Clinical Development - The company is currently executing three clinical programs, with Phase 2 MaGic results for DNTH103 expected in September [3] - Dr. Read expressed confidence in the potential of DNTH103 as a best-in-class therapy for patients with severe neuromuscular conditions [3]
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors